DESPITE some bad impression the Ivermectin, a Nobel prize-winning drug with a wide margin of safety and decades of safety data, has received recently due to overdose cases, to form an educated opinion on it we must look at the whole spectrum of information comprising only scientific facts and hard empirical evidence.
This is especially important when the drug may have a potential to provide a safety bridge to full vaccination (but not vaccine substitution in any measure) without devastating the economy and keep our back, even in the presence of variants, should the current vaccines start failing us.
First, we clarify that the following discussion is all about human-grade Ivermectin, while the animal-grade version is not for humans and its effects are largely unknown.
And even human-grade Ivermectin is strictly not for self-medication until proper guidance from the health authorities.
Furthermore, this discussion is not to provide ground to either proponents or opponents of Ivermectin but to invite both sides to relook into this issue in a more detailed and balanced way backed by science.
After all, we are not out of the wood yet with this pandemic, while the science behind Ivermectin may have a valuable piece of knowledge to face current and possible future pandemics.
SARS-CoV-2 is not the first virus to draw scientists' close attention to this drug.
Near five decades of scientific literature documents Ivermectin's potent virostatic effects on a broad range of RNA and DNA viruses such as Zika, dengue, yellow fever, West Nile, Human immunodeficiency virus type 1 and many others.
The recent research significantly expands understanding of the link between this humble de-wormer and various viral infections, including SARS-CoV-2.
Ivermectin, primarily discovered for its deworming function, acts on parasites' neural and muscle cells by hyperpolarising them, interrupting proper functioning and causing paralysis and death for parasites.
Though the drug is safe for humans in therapeutic doses (FDA approved) of 150 – 200 μg per kg of body weight and even higher doses as documented in the literature in various protocol regimes.
However, if Ivermectin crosses the blood-brain barrier, it may cause brain damage.
In other words, it is not to be consumed by those with a compromised blood-brain barrier—for example, meningitis patients, children below two years old or below 15 kg weight, and pregnant or breastfeeding women due to danger for the child.
Furthermore, people with impaired liver or kidney function should also be cautious with Ivermectin. However, many people might be unaware of their liver or kidney malfunction, which underscores once again that Ivermectin is strictly not for self-medication.
But research discovers that Ivermectin's beneficial functions do not stop at paralysing worms and here science gets exciting.
Although Ivermectin does not kill the virus directly, its several mechanisms inhibit viral replication and could be best described as having a virostatic effect.
First, Ivermectin is found to inhibit SARS-CoV-2 ability (and primary target) to suppress the host's cellular defensive mechanisms.
As a result, the cell can recognise the viral intrusion and ramp up not only its own defence but inform the neighbouring cells to ramp up their defences as well.
Furthermore, Ivermectin exhibits relatively high binding efficacy to SARS-CoV-2 RNA-dependent RNA polymerase (RdRp)—the essential protein for viral replication inside the host's cells.
By blocking RdRp, Ivermectin halts the replication of SARS-CoV-2 viral RNA, rendering newly formed viral copies hollow and useless.
Additionally, in silico examinations of molecular docking capabilities revealed that Ivermectin efficiently binds to the SARS-CoV-2 S-protein as well as to the human cell receptors ACE-2.
While being sandwiched between these two structures, Ivermectin can prevent viral entry into human cells.
Ivermectin also appears to have potent anti-inflammatory action. It is found to downregulate lipopolysaccharide-induced production of inflammatory cytokines in vitro and in vivo in mice, while SARS-CoV-2 triggers inflammation through a mechanism similar to that of lipopolysaccharides.
On top of all that, Ivermectin possibly reduces blood-vessel clotting observed in SARS-CoV-2 patients. The malaria parasite is well known to cause Red Blood Cells (RBC) clumping due to simultaneous binding with multiple RBCs via the CD147 receptor, which it uses to penetrate RBC.
The same CD147 receptor is identified as a key binding site, apart from ACE2, for SARS-CoV-2 S-protein and therefore possibly contributing to blood clotting by binding only.
This possibly explains reduced odds of severe disease outcomes among individuals with O blood group observed for malaria and SARS-CoV-2 alike due to lower CD147 density on RBCs of this blood type.
As mentioned above the Ivermectin molecule can bind with S-protein and therefore reduce blood clotting in SARS-CoV-2.
The figure below illustrates the concept.
The above scientific rationale made Ivermectin one of the most looked into potential repurposed drugs for COVID-19 management at all stages—from the prophylaxis to critical care.
The most recent, comprehensive and methodology-robust meta-analytical systematic reviews on efficacy and safety of Ivermectin therapy against COVID-19 which restricted the included studies to the highest level of evidence, that is, randomized clinical trials (RCTs) were published on June 6 2021 (based on 19 RCTs) and June 21 2021 (based on 24 RCTs).
To remind, meta-analysis is a systematic statistical method of summarising empirical findings from several similar studies with due consideration of any flaws in the evidence.
Both of the above mentioned meta-analytical studies came to similar conclusion that Ivermectin was associated with reduced risk of mortality and progression to severe disease in COVID-19 management.
The latter study also found that Ivermectin prophylaxis reduced COVID-19 infection by an average of 86% but graded this finding as low-certainty due to underlying study design limitations and fewer included trials.
There were too few adverse events reported which were not clearly associated with the use of Ivermectin and also minor and transitory in nature.
However, another recent meta-analytical review published on July 28 2021 in Cochrane Library—database highly regarded in the medical field, found no evidence of Ivermectin benefits in COVID-19 treatment.
One important variable that might explain these contradictory results between meta-analytical studies is dosage and protocol.
Indeed, majority of the studies included in Cochrane review, in contrast with to other reviews, used very low, close to therapeutic dose of Ivermectin.
Meanwhile it is already generally understood in the medical field that even if Ivermectin is to have beneficial effect in COVID-19 treatment outcome it can be achieved mostly at higher than therapeutic doses.
Therefore future research, whether RCTs or meta-analytical reviews should gear towards ascertaining the effect of Ivermectin dose.
In light of the above scientific rationale and empirical evidence, the fact that Malaysia's authorities at last initiated their own Ivermectin clinical trial (I-TECH study) is a highly positive development.
Although, it could have been done earlier.
Furthermore it is positive that the target cohort for I-TECH study is those in the very early stage of the disease (Stage 2-3)—admitted to hospitals or placed in the quarantine centres.
This is because the use of Ivermectin as an early treatment for those who have no immunity against COVID-19 (natural or vaccine-induced) has the greatest potential to effectively flatten the curve without economic collapse—form of a safety bridge to the time of full vaccination.
Furthermore, given the current public pressure for Ivermectin treatment and anecdotal evidence of its ongoing unauthorised use, volunteers recruitment can be expediated.
Should the study show positive results the strategy is clear—massive and quick testing and early Ivermectin treatment for those with no immunity against COVID-19.
This is similar to what Peru authorities have done in May 2020—one of the largest documented case studies on the population-wide use of Ivermectin for Covid-19 treatment with apparent success.
Importantly, note that most of the identified mechanisms of action on SARS-CoV-2 by Ivermectin are not impacted by the presence of SARS-CoV-2 variants.
Therefore, this drug has the potential to keep our back in case if current vaccines start losing their efficacy in the face of new variants.
Meanwhile, it is worrying that anecdotal evidence suggests ongoing unauthorised sale and re-sale of the Ivermectin in Malaysia and lives of Malaysians are in double jeopardy due to concern over the drug's authenticity and its use without proper medical guidance in terms of dosage, protocol or contraindications, and supervision.
Hopefully, health authorities can come up with some swift and definitive actions on all of the above.
Rais Hussin and Margarita Peredaryenko are part of the research team at EMIR Research, an independent think tank focused on strategic policy recommendations based on rigorous research.
This article holds the view of the author and does not necessarily reflect the views of the Astro AWANI editorial board.
AWANI Columnist
Thu Aug 26 2021
Even human-grade Ivermectin is strictly not for self-medication until proper guidance from the health authorities. - Filepic
SPR India tuntut maklum balas aduan terhadap Modi, Rahul Gandhi
Suruhanjaya Pilihan Raya India hari ini memaklumkan pihaknya sudah meminta maklum balas daripada parti pemerintah Bharatiya Janata Party (BJP) dan parti pembangkang, Kongres.
Penguin maharaja berdepan kepupusan akibat pencairan ais
Spesies penguin terbesar di dunia, penguin maharaja terus berdepan ancaman apabila habitatnya terjejas akibat perubahan iklim. Selain pernah disifatkan bakal pupus menjelang tahun 2050, saintis dari Pusat Penyelidikan British Antarctic Survey pada Khamis memberitahu perubahan iklim memberi kesan terhadap kecairan ais di wilayah beku Antartika yang menjadi habitat buat koloni penguin maharaja.
ANCC2024: Astro, NACSA bekerjasama anjur 'coding challenge'
Diilhamkan daripada komitmen Astro dan NACSA untuk memupuk langkah keselamatan siber yang proaktif, pertandingan itu juga bertujuan untuk menormalisasikan navigasi digital yang selamat dalam ruang siber.
Suhu cecah 42 Celsius, Bangladesh tutup semua sekolah sehingga Sabtu ini
Suhu panas melampau sehingga mencecah 42 Celcius memaksa kerajaan Bangladesh menutup operasi persekolahan yang melibatkan 33 juta pelajar di negara itu.
PM Haiti serah surat peletakan jawatan
Perdana Menteri Haiti, Ariel Henry akhirnya menyerahkan surat peletakan jawatan pada Khamis selepas tidak henti berdepan tekanan antarabangsa bagi mengawal kekacauan kumpulan pengganas di negara itu. Surat rasmi peletakan jawatan yang ditandatangani Ariel Henry diserahkan di Los Angeles dan dikongsi pejabat Perdana Menteri Haiti bersamaan tarikh majlis presiden peralihan ditubuhkan.
RTS JB-Singapura di landasan tepat
Perkambangan pembinaan Projek RTS Johor Bahru-Singapura dilihat berada pada landasan tepat.
Rakyat Israel sudah mula misi bina penempatan kekal di Gaza
Sekumpulan warga Israel yang bermalam di sempadan berarak memasuki Gaza pada pagi Khamis dengan matlamat untuk membuka penempatan kekal di wilayah itu. Dalam poster kumpulan itu yang tular di media sosial, tertera slogan 'tentera telah mendudukinya, maka kami akan menetap disitu'.
Malaysia sebuah negara selamat - Kedutaan AS
Kedutaan Amerika Syarikat di Malaysia menyangkal dakwaan dangkal Profesor Bruce Gilley yang mengatakan Malaysia adalah negara tidak selamat dilawati.
Memetik laporan Free Malaysia Today, pihak kedutaan berkata tiada perubahan kepada nasihat perjalanan yang kekal pada tahap satu, iaitu tahap paling rendah daripada empat tahap.
Memetik laporan Free Malaysia Today, pihak kedutaan berkata tiada perubahan kepada nasihat perjalanan yang kekal pada tahap satu, iaitu tahap paling rendah daripada empat tahap.
Menteri Luar Malaysia perkukuh hubungan dengan China
Menteri Luar Datuk Seri Mohamad Hasan mengadakan perbincangan substantif dengan rakan sejawatannya, Wang Yi, dalam lawatan pertama beliau ke China sejak memegang jawatan itu pada Disember 2023.
Kakitangan bakal terima tunggakan gaji dalam tempoh 30 bulan
Isu tunggakan gaji membabitkan 20 bekas kakitangan Kedah Agro Holdings Berhad (KAHB) selama sembilan bulan dijangka selesai dalam waktu terdekat selepas kesemua mereka akan menerima bayaran secara berperingkat dalam tempoh 30 bulan berjumlah RM337,000.
Ivermectin tidak berkesan cegah gejala teruk COVID-19 - Kajian penyelidik Malaysia
Kumpulan penyelidik Malaysia dipetik sebagai berkata, penemuan mereka itu sekali gus tidak menyokong penggunaan Ivermectin untuk pesakit COVID-19.
KKM cadang laksana kajian klinikal guna Ivermectin ke atas kontak rapat COVID-19
Institut Penyelidikan Klinikal Kebangsaan (ICR) masih menunggu kelulusan dari Bahagian Regulatori Farmasi Negara (NPRA) untuk melaksanakan kajian klinikal ini.
Tidak kurangkan risiko COVID-19, KKM tidak syorkan Ivermectin - Dr Noor Hisham
Keputusan itu dikeluarkan susulan hasil dapatan kajian Ivermectin (I-Tech) ke atas 500 pesakit COVID-19 melibatkan kategori 2 atau 3.
Keputusan kajian Ivermectin akan dibentangkan minggu hadapan
Khairy berkata kajian tempatan berkaitan ubat tersebut sudah selesai dan keputusan sudah diperolehi.
Penjualan Ivermectin: Polis sedia bantu KKM - Mazlan
Polis sedia membantu jika pihak Kementerian Kesihatan (KKM) membuat aduan berhubung penjualan secara haram ubat Ivermectin sebagai penawar COVID-19.
Penggunaan Ivermectin hanya untuk tujuan ujian klinikal - MPS
KKM akan menjalankan ujian klinikal terhadap 500 pesakit, untuk menilai keberkesanan penggunaan Ivermectin.
Jual ubat Ivermectin: 'KKM, MCMC jangan lepas tangan' - Persatuan Farmasi Malaysia
Tindakan berani pihak yang cuba mengambil kesempatan itu adalah salah di bawah Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956.
Penjual ubat Ivermectin berdepan tindakan
Amrahi menggesa agar kerajaan mengambil tindakan terhadap penjualan ubat ini sama ada secara dalam talian atau dibawa masuk dari luar negara.
Mesyuarat Khas Parlimen: Ahli Parlimen PH dikritik desak guna Ivermectin rawat COVID-19
Beberapa Ahli Parlimen pembangkang dikiritik pengamal perubatan dan netizen kerana mendesak Kementerian Kesihatan (KKM) meluluskan penggunaan Ivermectin untuk merawat pesakit COVID-19.
Penggunaan Ivermectin: Tunggu keputusan ujian klinikal KKM - Pakar kesihatan
sebarang keputusan akan dibuat berdasarkan evidence-based medicine, dan KKM dijangka mengeluarkan keputusan berhubung ujian klinikal Ivermectin pada September ini.